SeaCrest Wealth Management’s Galmed Pharmaceuticals GLMD Stock Holding History

SeaCrest Wealth Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3	Closed	-$4K	–	1029
2019 Q1	$4K	Hold	3	–	–	﹤0.01%	1773
2018 Q4	$3K	Hold	3	–	–	﹤0.01%	1818
2018 Q3	$7K	Hold	3	–	–	﹤0.01%	1761
2018 Q2	$6K	Buy	+3	New	+$4.34K	﹤0.01%	1765

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

FMBTD

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

PAM

Premier Asset Management Chicago, Illinois $79.6M AUM 10.77% 1-Year Est. Return

SeaCrest Wealth Management's GLMD Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Galmed Pharmaceuticals (GLMD) in Q2 2019, closing a stake of 3 shares — an estimated $4K sold.

SeaCrest Wealth Management first reported a position in GLMD in Q2 2018 and held it in 4 quarters. The position peaked at $7K in Q3 2018. 34 funds tracked by Wall St. Rank hold GLMD as of Q2 2019.

SeaCrest Wealth Management reported no remaining Galmed Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 3 Galmed Pharmaceuticals shares in Q2 2019, an estimated $4K.
SeaCrest Wealth Management first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 4 quarters.
SeaCrest Wealth Management's Galmed Pharmaceuticals position peaked at $7K in Q3 2018.
34 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.